This page contains brief details about the drug , it's indication, dosage & administaration, mechanism of action, related brands with strength, warnings and common side effects.

Background and Date of Approval

Axitinib is an antineoplastic agent which was approved for its medical use on 27th January 2012.

Mechanism of Action of undefined

Axitinib is a biological agent that acts as targeted drug therapy in cancer treatment. It is an anticancer medication that belongs to the category of tyrosine kinase inhibitors. It interferes with the growth of blood vessels inside the cancer cells and also acts against proteins called receptor tyrosine kinases to interrupt cell signaling, ultimately stopping the growth and spread of cancer cells.

Uses of undefined

Axitinib has been developed to treat a type of kidney cancer (Renal cell carcinoma) after disease progression and inadequate response to other anticancer therapies.

undefined Drug administaration and Dosage available

Axitinib is available in the form of film-coated tablets in doses of 1mg, 3mg, 5mg, and 7mg. The usual recommended dose is 5mg twice a day. Your healthcare provider will adjust the dosing according to how well your body tolerates this medication.

Warnings, Precautions and Side Effects of undefined


Contact your doctor immediately if you experience shortness of breath, rapid heartbeat, stomach pain, or severe bleeding. During the Axitinib treatment, your doctor may periodically monitor your complete blood counts, blood sugar, electrolytes, thyroid panel, urine test (for proteinuria), and kidney parameters to prevent serious complications. Report to your doctor if you have been diagnosed with diabetes, hypertension, problems in your heart, liver, skin, kidneys, or blood disorders. It is not recommended to undergo surgical procedures while on treatment with an Axitinib Tablet due to the high risk of bleeding. Tell your physician before you undergo surgery or dental procedures. Get immediate medical attention if you experience itching, vision changes, confusion, or dizziness. 


Axitinib may cause harm to an unborn baby. Tell your healthcare provider before beginning this treatment if you are pregnant or planning to have a baby. It is advised for both men and women to follow proper contraceptive methods during and one week after the last dose of Axitinib. Avoid breastfeeding your baby while you are on the treatment as Axitinib can impact the growth and development of the baby by passing into the breast milk.

Side Effects

The common side effects that are likely to occur while you are on the treatment with Axitinib are high blood pressure, diarrhoea, nausea, vomiting, constipation, indigestion, soreness in the mouth, tongue or throat, shortness of breath, cough, tiredness, weakness, dehydration, loss of appetite, joint pain, weight loss, headache, muscle pain, nose bleeding, tinnitus, itching, hair loss, dizziness, and inflammation of the gallbladder. If you experience severe headache, chest pain, blood in cough, weakness on one side of the body, trouble speaking, or confusion, report to your doctor immediately.

Word Of Advice

Axitinib can make you feel dizzy and weak. Avoid driving or operating heavy machines if you experience dizziness, confusion, or tiredness while on treatment with Axitinib. Grapefruit or grapefruit juice may also increase axitinib plasma concentrations and should be avoided. Some formulations of gefitinib may contain lactose as an inactive ingredient in which the body is unable to digest lactose, a sugar found in milk and dairy products. It can cause symptoms such as bloating, and abdominal pain. If you have lactose intolerance, inform your doctor before starting this therapy. It is advised to avoid high-fiber foods and drink lots of fluids if you have severe diarrhea.

Frequently Asked Question


  1. Pfizer, [Revised on 13th Jan 2020] [Accessed on 23rd March 2023],
  2. Pfizer Labs, Electronic Medicines Compendium(EMC), [Revised on Mar 2021] [Accessed on 23rd March 2023],
  3. Pfizer, Fact sheet, [Revised on Sep 2012] [Accessed on 23rd March 2023],
  4. Annex I summary of Product Characteristics - European Medicines Agency. Available at: (Accessed on March 25, 2023).
  5. Edward Chu, Cancer Chemotherapy, Lange’s Basic and Clinical Pharmacology, 14th Edition, 2018, 948-976.


The drug information on this page is not a substitute for medical advice, it is meant for educational purposes only. For further details consult your doctor about your medical condition to know if you are eligible to receive this treatment.